Skip to main content
TipRanks
Go Ultimate75% OFF

Monopar Therapeutics Inc (MNPR) Stock Price & Analysis

582 Followers

MNPR Stock Chart & Stats

$70.29-$0.46(-0.65%)
At close: 4:00 PM EST
$75$100$125Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$68.69 - $72.80
52-Week Range
$50.07 - $124.82
Previous Close
$70.75
Volume
N/A
Average Volume (3M)
146.78K
Market Cap
$476.34M
Enterprise Value
$552.84M
Total Cash (Recent Filing)
$129.45M
Total Debt (Recent Filing)
$357.26K
Price to Earnings (P/E)
―
Beta
1.54
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage limits refinancing and solvency pressure, which is valuable for a pre-revenue biotechnology company facing uncertain development timelines. A comparatively under-levered balance sheet preserves flexibility to fund research, absorb setbacks, and pursue financing without adding substantial debt-service obligations.

Balance Sheet Flexibility

A meaningful equity and asset base relative to debt provides financial capacity while the company advances drug candidates toward clinical milestones. This structure can support continued development and reduce dependence on debt markets, although it does not remove the need for future capital.

Development-Focused Pipeline

Internal development keeps the company focused on advancing targeted therapeutics for cancer and other serious diseases rather than maintaining a broad commercial operating structure. Progress through preclinical and clinical stages could create strategic value if candidates demonstrate efficacy and reach later development milestones.

Bears Say

No Product Revenue

The absence of revenue leaves the company without an operating base to absorb research and corporate costs, making financial results dependent on spending levels and capital access. Until a candidate is commercialized or produces licensing income, earnings visibility and the ability to self-fund development remain weak.

Accelerating Cash Burn

Persistent negative cash generation reduces the funds available for ongoing operations and clinical development, while the sharper TTM burn indicates that funding needs are increasing. Continued consumption of cash can force additional capital raising and may constrain the pace or scope of future programs.

Deepening Losses

Persistent and substantially larger TTM losses indicate that expenses are rising without a revenue base to offset them. This weak profitability profile increases dependence on external funding, reduces tolerance for clinical or regulatory setbacks, and makes future earnings highly dependent on successful development outcomes.

Monopar Therapeutics Inc News

MNPR FAQ

What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $50.07 and its highest was $124.82 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $476.34M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Nov 06, 2026. The company reported -$0.724 earnings per share for the quarter, missing the consensus estimate of -$0.715 by -$0.009.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,776,773 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.724 in its last earnings report, missing expectations of -$0.715. Following the earnings report the stock price went up 6.248%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Hedge funds hold Monopar Therapeutics Inc shares: the largest hedge-fund position in Monopar Therapeutics Inc is 72,418,493 shares, and hedge funds decreased their holdings by 145.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology